Ninlaro® (ixazomib) is an oral proteasome inhibitor that was approved by the FDA in the fall of 2105 to treat multiple myeloma in combination with the medicines lenalidomide and dexamethasone, in people who have received at least one prior treatment for their multiple myeloma. It may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
| SparkCures ID | 36 |
|---|---|
| Developed By | Takeda Oncology |
| Brand Name | Ninlaro® |
| Generic Name | Ixazomib |
| Additional Names | MLN9708 |
| Treatment Classifications | |
| Tags |
|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.